Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Subang Jaya 47500, Selangor, Malaysia.
Medicina (Kaunas). 2021 Nov 16;57(11):1252. doi: 10.3390/medicina57111252.
: Lung cancer is the second most common cancer in the world. Non-small-cell lung carcinoma (NSCLC) makes up 85% of all lung cancer cases and the majority of patients are diagnosed when the cancer is advanced. Over the years, many anticancer drugs have been designed and introduced into the market to treat patients with advanced NSCLC. This review aims to discuss the comparative therapeutic benefits of conventional chemotherapeutics and other drugs available for treating advanced NSCLC. A literature search for first-line treatment of advanced NSCLC was carried out on PubMed and Google Scholar. Objective response rate (ORR) and overall survival were chosen as target endpoints. Monotherapy showed lower treatment endpoints compared to combination therapy. Different combinations of platinum-based doublets demonstrated similar efficacies in treating NSCLC. However, pemetrexed-platinum doublets showed significantly better treatment endpoint in patients with non-squamous NSCLC. Most studies showing the best complete response rate (CRR) utilized epidermal growth factor receptor ( tyrosine kinase inhibitors (), while most studies producing the best overall survival included programmed death-1/programmed death-ligand 1 (/ inhibitors in their treatment regimens. The findings of this review indicate that targeted therapy using specific inhibitors is now the most promising first-line anticancer treatment available in the market. However, chemotherapy is still effective in treating advanced NSCLC and is viable as a first-line treatment.
肺癌是全球第二大常见癌症。非小细胞肺癌（NSCLC）占所有肺癌病例的 85%，大多数患者在癌症晚期被诊断出来。多年来，已经设计并推出了许多抗癌药物来治疗晚期 NSCLC 患者。本综述旨在讨论常规化疗药物和其他治疗晚期 NSCLC 的药物的比较治疗益处。
在 PubMed 和 Google Scholar 上对晚期 NSCLC 的一线治疗进行了文献检索。客观缓解率（ORR）和总生存期被选为目标终点。
与联合治疗相比，单药治疗的治疗终点较低。不同的铂类双联方案在治疗 NSCLC 方面显示出相似的疗效。然而，培美曲塞-铂类双联方案在非鳞状 NSCLC 患者中显示出更好的治疗终点。显示最佳完全缓解率（CRR）的大多数研究都利用了表皮生长因子受体（tyrosine kinase inhibitors ()，而产生最佳总生存期的大多数研究都在其治疗方案中包含程序性死亡-1/程序性死亡配体 1 () 抑制剂。
本综述的结果表明，使用特定抑制剂的靶向治疗现在是市场上最有前途的一线抗癌治疗方法。然而，化疗在治疗晚期 NSCLC 方面仍然有效，并且是一种可行的一线治疗方法。
